Asensus Surgical (TRXDW) 10-Q 9 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 02, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Trading Symbol	TRXC
Entity Registrant Name	TRANSENTERIX INC.
Entity Central Index Key	876,378
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		100,142,684

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Sales		$ 61		$ 267
Operating Expenses
Cost of goods sold		202		660
Research and development	$ 7,048	9,067	$ 21,111	21,960
Sales and marketing	413	456	1,161	1,323
General and administrative	1,762	1,481	5,607	4,757
Amortization of intangible assets	338	125	589	376
Acquisition related costs	4,003		4,003
Total Operating Expenses	13,564	11,331	32,471	29,076
Operating Loss	(13,564)	(11,270)	(32,471)	(28,809)
Other Expense
Interest Expense, net	(436)	(237)	(997)	(764)
Total Other Expense, net	(436)	(237)	(997)	(764)
Loss before income taxes	(14,000)	(11,507)	(33,468)	(29,573)
Income tax benefit	99		99
Net loss	(13,901)	(11,507)	(33,369)	(29,573)
Other comprehensive loss
Foreign currency translation loss	(429)		(429)
Comprehensive loss	$ (14,330)	$ (11,507)	$ (33,798)	$ (29,573)
Net loss per share - basic and diluted	$ (0.16)	$ (0.18)	$ (0.46)	$ (0.52)
Weighted average common shares outstanding - basic and diluted	86,044	63,068	72,713	57,212

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 52,893	$ 34,766
Accounts receivable, net	78	133
Inventories	3,435
Interest receivable	6	1
Other current assets	5,450	740
Total Current Assets	61,862	35,640
Restricted cash	0	250
Property and equipment, net	4,388	3,120
Intellectual property, net	63,866	2,241
Trade names, net	6	7
In-process research and development	22,197
Goodwill	116,054	93,842
Other long term assets	59	11
Total Assets	268,432	135,111
Current Liabilities
Accounts payable	4,394	1,768
Accrued expenses	6,160	1,769
Notes payable - current portion	4,780	610
Total Current Liabilities	15,334	4,147
Long Term Liabilities
Contingent consideration	24,300
Long-term deferred tax liabilities	21,218
Notes payable - less current portion, net of debt discount	14,884	9,175
Total Liabilities	$ 75,736	$ 13,322
Commitments and Contingencies
Stockholders' Equity
Common stock $0.001 par value, 750,000,000 shares authorized at September 30, 2015 and December 31, 2014; 100,103,989 and 63,182,806 shares issued at September 30, 2015 and December 31, 2014, respectively; and 100,102,816 and 63,182,806 shares outstanding at September 30, 2015 and December 31, 2014, respectively	$ 100	$ 63
Additional paid-in capital	362,313	257,642
Accumulated deficit	(169,285)	(135,916)
Treasury stock at cost, 1,173 and 0 shares at September 30, 2015 and December 31, 2014, respectively	(3)
Accumulated other comprehensive loss	(429)
Total Stockholders' Equity	192,696	121,789
Total Liabilities and Stockholders' Equity	$ 268,432	$ 135,111

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Statement of Partners' Capital [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	100,103,989	63,182,806
Common stock, shares outstanding	100,102,816	63,182,806
Treasury stock, shares	1,173	0

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - 9 months ended Sep. 30, 2015 - USD ($) $ in Thousands	Total	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Balance at Dec. 31, 2014	$ 121,789	$ 63		$ 257,642	$ (135,916)
Balance, Shares at Dec. 31, 2014		63,183,000
Stock-based compensation	2,388			2,388
Issuance of common stock, net of issuance costs	58,295	$ 21		58,274
Issuance of common stock, net of issuance costs, Shares		20,756,000
Issuance of common stock, acquisition	43,677	$ 15		43,662
Issuance of common stock, acquisition, Shares		15,543,000
Exercise of stock options and restricted stock	252	$ 1		251
Exercise of stock options and restricted stock, Shares		622,000
Return of common stock to pay withholding taxes on restricted stock	(3)		$ (3)
Return of common stock to pay withholding taxes on restricted stock, Shares		(1,000)	1,000
Issuance of warrants	96			96
Other comprehensive loss	(429)					$ (429)
Net loss	(33,369)				(33,369)
Balance at Sep. 30, 2015	$ 192,696	$ 100	$ (3)	$ 362,313	$ (169,285)	$ (429)
Balance, Shares at Sep. 30, 2015		100,103,000	1,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating Activities
Net loss	$ (33,369)	$ (29,573)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
Depreciation and amortization	1,391	936
Amortization of debt discount and debt issuance costs	89	57
Stock-based compensation	2,388	2,018
Loss on disposal of property and equipment	34	5
Deferred tax benefit	(99)
Changes in operating assets and liabilities, net of effect of acquisition:
Accounts receivable	133	150
Interest receivable	(5)	68
Inventories	(250)	434
Other current and long term assets	(248)	(241)
Restricted cash	250	125
Accounts payable	984	1,461
Accrued expenses	4,127	350
Net cash and cash equivalents used in operating activities	(24,575)	(24,210)
Investing Activities
Proceeds from sale and maturities of investments		6,191
Proceeds from sale of property and equipment		25
Payments for acquisition	(25,000)
Purchase of property and equipment	(728)	(1,626)
Net cash and cash equivalents (used in) provided by investing activities	(25,728)	4,590
Financing Activities
Payment of debt		(2,877)
Proceeds from issuance of common stock, net of issuance costs	58,295	52,433
Proceeds from issuance of debt, net of debt discount	9,886	4,321
Taxes paid related to net share settlement of vesting of restricted stock units	(3)
Proceeds from exercise of stock options and warrants	252	73
Net cash and cash equivalents provided by financing activities	68,430	53,950
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase in cash and cash equivalents	18,127	34,330
Cash and Cash Equivalents, beginning of period	34,766	10,014
Cash and Cash Equivalents, end of period	52,893	44,344
Supplemental Disclosure for Cash Flow Information
Interest paid	$ 598	$ 518
Supplemental Schedule of Noncash Investing and Financing Activities
Issuance of common stock warrants	96	54
Contingent consideration related to acquisition	$ 24,300
Issuance of common stock related to acquisition	$ 43,677

Organization and Capitalization

Organization and Capitalization	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Organization and Capitalization	1. Organization and Capitalization TransEnterix, Inc. (the “Company”) is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical challenges associated with current laparoscopic and robotic options. The Company is focused on the development and commercialization of the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform, and the commercialization of ALF-X ® The SurgiBot System is designed to utilize flexible instruments through articulating channels controlled directly by the surgeon, with robotic assistance, while the surgeon remains patient-side within the sterile field. The flexible nature of the SurgiBot System allows for multiple instruments to be introduced and deployed through a single site, thereby offering room for visualization and manipulation once inside the body. The SurgiBot System also allows for three-dimensional high definition (“3DHD”) vision technology. The ALF-X System is a multi-port robotic surgery system which allows up to four arms to control robotic instruments and a camera. The system features advanced technology to enable surgeons with haptic feedback and the ability to move the camera via eye movement. The system replicates laparoscopic motion that is familiar to experienced surgeons, and features 3DHD vision technology. The ALF-X System also offers responsible economics to hospitals by offering robotic technology with reusable instruments with minimal additional costs per surgery. On September 3, 2013, TransEnterix Surgical, Inc. a Delaware corporation (“TransEnterix Surgical”), and SafeStitch Medical, Inc., a Delaware corporation (“SafeStitch”) consummated a merger transaction whereby TransEnterix Surgical merged with a merger subsidiary of SafeStitch, with TransEnterix Surgical as the surviving entity in the merger (the “Merger”). As a result of the Merger, TransEnterix Surgical became a wholly owned subsidiary of SafeStitch. On December 6, 2013, SafeStitch changed its name to TransEnterix, Inc. and increased the authorized shares of common stock from 225,000,000 to 750,000,000, and authorized 25,000,000 shares of preferred stock, par value $0.01 per share. Prior to the Merger, SafeStitch was focused on developing its Gastroplasty Device for the treatment of obesity, gastroesophageal reflux disease (“GERD”) and Barrett’s Esophagus. In the second quarter of 2014, the Company ceased internal development of the Gastroplasty Device and is currently evaluating strategic alternatives for the former SafeStitch products. On September 18, 2015, the Company entered into a Membership Interest Purchase Agreement, (the “Purchase Agreement”) with SOFAR S.p.A., (“SOFAR”) as seller, Vulcanos S.r.l. (“Vulcanos”), as the acquired company, and TransEnterix International, Inc. (“TransEnterix International”), a direct, wholly owned subsidiary of the Company which was incorporated in September 2015, as buyer. The closing of the transactions occurred on September 21, 2015 (the “Closing Date”) pursuant to which the Company acquired all of the membership interests of Vulcanos from SOFAR (the “ALF-X Acquisition”), and changed the name of Vulcanos to TransEnterix Italia S.r.l (“TransEnterix Italia”). The acquisition included all of the assets, employees and contracts related to the ALF-X System. See Note 5 for a description of the related transactions. As used herein, the term “Company” refers to the combination of SafeStitch and TransEnterix Surgical after giving effect to the Merger, and TransEnterix International and TransEnterix Italia after giving effect to the ALF-X Acquisition, the term “SafeStitch” refers to the historic business of SafeStitch Medical, Inc. prior to the Merger, and the term “TransEnterix Surgical” refers to the historic business of TransEnterix Surgical, Inc. prior to the Merger. The Company operates in one business segment. The Company is subject to a number of risks similar to other similarly-sized companies in the medical device industry. These risks include, without limitation, the historical lack of profitability; the Company’s ability to raise additional capital; its ability to successfully integrate the ALF-X System into its business; its ability to successfully develop, clinically test and commercialize its products; the timing and outcome of the regulatory review process for its products; changes in the health care and regulatory environments of the United States, Italy and other countries in which the Company intends to operate; its ability to attract and retain key management, marketing and scientific personnel; competition from new entrants; its ability to successfully prepare, file, prosecute, maintain, defend and enforce patent claims and other intellectual property rights; its ability to successfully transition from a research and development company to a marketing, sales and distribution concern; competition in the market for robotic surgical devices; and its ability to identify and pursue development of additional products.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of presentation The Company has prepared the accompanying unaudited consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements are unaudited and should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on February 20, 2015. The accompanying unaudited interim consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of the Company’s management, necessary for a fair statement of the Company’s consolidated financial position, results of operations and cash flows for the periods presented. These principles require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The principal estimates relate to inventory valuation, stock-based compensation, accrued expenses and income tax valuation. Actual results could differ from those estimates. The year-end balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. For a description of our critical accounting policies and estimates, please refer to the “Critical Accounting Policies and Estimates” section of the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on February 20, 2015. There have been no material changes in any of our accounting policies since December 31, 2014. Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis. The Company has accumulated a deficit of approximately $169.3 million as of September 30, 2015, a net loss of approximately $33.4 million for the nine months ended September 30, 2015, and has not generated significant revenue or positive cash flows from operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty. To meet its capital needs, the Company is considering multiple alternatives, including, but not limited to, additional equity financings, debt financings and other funding transactions. There can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. If the Company is unable to obtain the necessary capital, it will need to pursue a plan to license or sell its assets, seek to be acquired by another entity and/or cease operations. Consolidation The accompanying consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries, SafeStitch LLC, TransEnterix Surgical, Inc., TransEnterix International, Inc. and TransEnterix Italia. All inter-company accounts and transactions have been eliminated in consolidation. Reverse Merger On September 3, 2013, TransEnterix Surgical and SafeStitch, consummated the Merger whereby TransEnterix Surgical merged with a merger subsidiary of SafeStitch, with TransEnterix Surgical as the surviving entity in the Merger. As a result of the Merger, TransEnterix Surgical became a wholly owned subsidiary of SafeStitch. On December 6, 2013, SafeStitch changed its corporate name to TransEnterix, Inc. The Reverse Merger has been accounted for as a reverse acquisition under which TransEnterix Surgical was considered the acquirer of SafeStitch. As such, the financial statements of TransEnterix Surgical are treated as the historical financial statements of the combined company, with the results of SafeStitch being included from September 3, 2013. As a result of the Reverse Merger with SafeStitch, historical common stock amounts and additional paid in capital have been retroactively adjusted using an Exchange Ratio of 1.1533. Reverse Stock Split On March 31, 2014, the Company effectuated a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1 for 5 (the “Reverse Stock Split”). As a result of the Reverse Stock Split, the Company’s issued and outstanding stock decreased from 244,276,923 to 48,855,255 shares of common stock, all with a par value of $0.001. All information related to common stock, stock options, restricted stock units, warrants and earnings per share for prior periods has been retroactively adjusted to give effect to the Reverse Stock Split, except for the reference to the Merger Exchange Ratio of 1.1533. Inventories Inventories are stated at the lower of cost or market. Cost is based on the first in, first out method. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis. Identifiable Intangible Assets and Goodwill Identifiable intangible assets are recorded at cost, or when acquired as part of a business acquisition, at estimated fair value. Certain intangible assets are amortized over 7 to 10 years. Similar to tangible personal property and equipment, the Company periodically evaluates identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. No impairment existed at September 30, 2015 or December 31, 2014. Indefinite-lived intangible assets, such as goodwill, are not amortized. The Company tests the carrying amounts of goodwill for recoverability on an annual basis at December 31st or when events or changes in circumstances indicate evidence of potential impairment exists, using a fair value based test. No impairment existed at September 30, 2015 or December 31, 2014. In-Process Research and Development In-process research and development (“IPR&D”) assets represent the fair value assigned to technologies that are acquired, which at the time of acquisition have not reached technological feasibility and have no alternative future use. IPR&D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development projects. During the period that the IPR&D assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if the Company becomes aware of any events occurring or changes in circumstances that indicate that the fair value of the IPR&D assets are less than their carrying amounts. If and when development is complete, which generally occurs upon regulatory approval, and the Company is able to commercialize products associated with the IPR&D assets, these assets are then deemed definite-lived and are amortized based on their estimated useful lives at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&D assets, calculated as the excess of carrying value of the IPR&D assets over fair value. Contingent Consideration Contingent consideration is recorded as a liability and is the estimate of the fair value of potential milestone payments related to business acquisitions. Contingent consideration is measured at fair value using a discounted cash flow model utilizing significant unobservable inputs including the probability of achieving each of the potential milestones and an estimated discount rate associated with the risks of the expected cash flows attributable to the various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected timelines for achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The fair value of the contingent consideration at each reporting date is updated by reflecting the changes in fair value in our statement of operations. Debt Issuance Costs The Company capitalizes costs associated with the issuance of debt instruments and amortizes these costs to interest expense over the term of the related debt agreement using the effective yield amortization method. Unamortized debt issuance costs will be charged to operations when indebtedness under the related credit facility is repaid prior to maturity. Translation of Foreign Currencies The functional currency of the Company’s foreign subsidiary, TransEnterix Italia, is its local currency. The assets and liabilities of the Company’s foreign subsidiary are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for a subsidiary using a functional currency other than the U.S. dollar is included in accumulated other comprehensive income or loss as a separate component of stockholders’ equity. The Company’s intercompany accounts are denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation adjustment in accumulated other comprehensive income or loss as a separate component of stockholders’ equity, while gains and losses resulting from the remeasurement of intercompany receivables from a foreign subsidiary for which the Company anticipates settlement in the foreseeable future are recorded in the consolidated statement of operations. The net gains and losses recorded in the consolidated statements of operations for the three and nine months ended September 30, 2015 were not significant. Business Acquisitions Business acquisitions are accounted for using the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) 805, “Business Combinations.” ASC 805 requires, among other things, that assets acquired and liabilities assumed be recognized at their fair values, as determined in accordance with ASC 820, “Fair Value Measurements,” as of the acquisition date. For certain assets and liabilities, book value approximates fair value. In addition, ASC 805 establishes that consideration transferred be measured at the closing date of the acquisition at the then-current market price, which may be different than the amount of consideration assumed in the pro forma financial statements. Under ASC 805, acquisition related costs (i.e., advisory, legal, valuation and other professional fees) and certain acquisition-related restructuring charges impacting the target company are expensed in the period in which the costs are incurred. The application of the acquisition method of accounting requires the Company to make estimates and assumptions related to the estimated fair values of net assets acquired. Significant judgments are used during this process, particularly with respect to intangible assets. Generally, intangible assets are amortized over their estimated useful lives. Goodwill and other indefinite-lived intangibles are not amortized, but are annually assessed for impairment. Therefore, the purchase price allocation to intangible assets and goodwill has a significant impact on future operating results. Impact of Recently Issued Accounting Standards In September 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory Reclassifications As a result of a recent acquisition, certain financial statement captions have been added and we have reclassified certain prior-period amounts on our Consolidated Statement of Operations to conform to the presentation for the current period. Such reclassifications have no effect on previously reported total assets, liabilities, stockholders’ equity or net loss. As previously disclosed, in April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	3. Income Taxes Income taxes have been accounted for using the liability method in accordance with ASC 740 “Income Taxes”. The Company computes its interim provision for income taxes by applying the estimated annual effective tax rate method. The Company estimates an annual effective tax rate of 2.85% for the year ending December 31, 2015. The Company incurred losses for the three and nine month periods ended September 30, 2015 and is forecasting additional losses through the year, resulting in an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2015. Due to the Company’s history of losses, there is not sufficient evidence to record a net deferred tax asset associated with the U.S. operations, accordingly. A full valuation allowance has been recorded related to the net deferred tax asset in that jurisdiction. Deferred tax assets and liabilities related to the TransEnterix Italia subsidiary have been recorded on a preliminary basis as a component of purchase accounting as of the acquisition date. The Company is recording an income tax benefit for the quarter ended September 30, 2015 in the amount of $99,000 in connection with the Italian taxing jurisdiction. There is no net deferred tax asset recorded in relation to TransEnterix Italia and accordingly no valuation allowance has been recorded in that jurisdiction. The Company’s effective tax rate for each of the nine month periods ended September 30, 2015 and 2014 was 0.297% and 0%, respectively. At September 30, 2015, the Company had no unrecognized tax benefits that would affect the Company’s effective tax rate.

Basic and Diluted Net Loss per

Basic and Diluted Net Loss per Share	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Basic and Diluted Net Loss per Share	4. Basic and Diluted Net Loss per Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Diluted potential common shares consist of incremental shares issuable upon exercise of stock options and warrants. In computing diluted net loss per share for the three and nine months ended September 30, 2015 and 2014, no adjustment has been made to the weighted average outstanding common shares as the assumed exercise of outstanding options and warrants would be anti-dilutive.

Acquisition of ALF-X Surgical R

Acquisition of ALF-X Surgical Robotic System/ Closing of 2013 Merger and Financing Transaction	9 Months Ended
	Sep. 30, 2015
Acquisition of ALF-X Surgical Robotic System/ Closing of 2013 Merger and Financing Transaction	15. Closing of 2013 Merger and Financing Transaction Pursuant to an Agreement and Plan of Merger dated August 13, 2013, as amended by a First Amendment dated August 30, 2013 (collectively, the “Merger Agreement”), on September 3, 2013, the Company consummated the Merger in which a wholly owned subsidiary of SafeStitch merged with TransEnterix Surgical. Under the terms of the Merger Agreement, TransEnterix Surgical remained as the surviving corporation and as a wholly owned subsidiary of SafeStitch. Pursuant to the Merger Agreement, each share of TransEnterix Surgical’s capital stock issued and outstanding immediately preceding the Merger was converted into the right to receive 1.1533 shares of the Company’s common stock, par value $0.001 per share, other than those shares of TransEnterix Surgical’s common stock held by non-accredited investors, which shares were instead converted into the right to receive an amount in cash per share of SafeStitch common stock equal to $1.08, without interest, which was the volume-weighted average price of a share of common stock on the OTCBB for the 60-trading day period ended on August 30, 2013 (one business day prior to the effective date of the Merger). Upon the closing of the Merger, and in accordance with the terms of the Merger Agreement, the Company issued an aggregate of 21,109,949 shares of the Company’s common stock as Merger consideration and paid $293,000 to unaccredited investors in lieu of common stock. Additionally, pursuant to the Merger Agreement, upon consummation of the Merger, the Company assumed all of TransEnterix Surgical’s options, whether vested or unvested, and warrants issued and outstanding immediately prior to the Merger at the same Exchange Ratio. During July 2013, TransEnterix Surgical issued promissory notes (the “Bridge Notes”) to related parties consisting of existing investors of TransEnterix Surgical, in the aggregate principal amount of $2.0 million, as contemplated by the Merger Agreement. The Bridge Notes bore interest at a rate of 8% per annum. The Bridge Notes were not secured by any collateral and were subordinated in right of payment to the loan evidenced by the Original Loan Agreement. The Bridge Notes were converted into Series B Preferred Stock of the Company at the effective time of the Merger. Concurrent with the closing of the Merger, and in accordance with the terms of the Securities Purchase Agreement, the Company consummated a private placement (the “Private Placement”) transaction in which it issued and sold shares of its Series B Convertible Preferred Stock, par value $0.01 per share (the “Series B Preferred Stock”) to provide funding to support the Company’s operations following the Merger. The Private Placement was done pursuant to a Securities Purchase Agreement (the “Securities Purchase Agreement”) with accredited investors (the “Investors”), the majority of which were considered related parties as existing investors in SafeStitch or TransEnterix Surgical. Under the Securities Purchase Agreement, the Company issued 7,544,704.4 shares of Series B Preferred Stock, each share of which is convertible, subject to certain conditions, into two shares of common stock, for a purchase price of $4.00 per share of Series B Preferred Stock, which was paid in cash, cancellation of certain Bridge Notes of TransEnterix Surgical or a combination thereof. Pursuant to the Securities Purchase Agreement, the Company issued and sold an additional 25,000 shares of Series B Preferred Stock within the period provided in the Securities Purchase Agreement resulting in gross proceeds to the Company of approximately $100,000. Each share of Series B Preferred Stock was converted into two shares of our common stock, par value $0.001 per share, on December 6, 2013. In connection with the Merger Agreement and the September 2013 private placement, certain of SafeStitch’s and TransEnterix Surgical’s former stockholders, comprising approximately 93% of our stock on the effective date of the Merger, entered into Lock-up and Voting Agreements, pursuant to which such persons agreed, subject to certain exceptions, not to sell, transfer or otherwise convey any of the Company’s securities held by them (collectively, “Covered Securities”) for one year following the September 3, 2013 closing date (the “Merger Closing Date”). The Lock-up and Voting Agreements provide that such persons may sell, transfer or convey: (i) up to 50% of their respective Covered Securities during the period commencing on the one-year anniversary of the Merger Closing Date and ending on the eighteen-month anniversary of the Merger Closing Date; and (ii) up to an aggregate of 75% of their respective Covered Securities during the period commencing on the eighteen-month anniversary of the Merger Closing Date and ending on the two-year anniversary of the Merger Closing Date. The restrictions on transfer contained in the Lock-up and Voting Agreements ceased to apply to the Covered Securities on September 3, 2015. At the closing of the Merger, each outstanding share of capital stock of TransEnterix Surgical was cancelled and extinguished and converted into the right to receive a portion of the Merger consideration in accordance with the Merger Agreement. The Bridge Notes were terminated at the closing of the Merger, and the holders of such Bridge Notes received Merger consideration in accordance with the Merger Agreement. The Merger effectuated on September 3, 2013 qualified as a tax-free reorganization under Section 368 of the Internal Revenue Code. As a result of the Merger, the utilization of certain tax attributes of the Company may be limited in future periods under the rules prescribed under Section 382 of the Internal Revenue Code. The Company’s assets and liabilities are presented at their preliminary estimated fair values, with the excess of the purchase price over the sum of these fair values presented as goodwill. The following table summarizes the purchase price (in thousands): Common shares outstanding at the date of Merger 12,350 Closing price per share $ 7.60 $ 93,858 Cash consideration 293 Total purchase price $ 94,151 The purchase price was allocated to the net assets acquired utilizing the methodology prescribed in ASC 805. The Company recorded goodwill of $93.8 million after recording net assets acquired at fair value as presented in the following table. The following table summarizes the allocation of the purchase price to the net assets acquired (in thousands): Cash and cash equivalents $ 597 Accounts receivable 54 Inventory 50 Other current assets 53 Property and equipment 185 Other long-term asset 2 Intangible assets 10 Goodwill 93,842 Total assets acquired $ 94,793 Accounts payable and other liabilities 642 Total purchase price $ 94,151 Following the announcement of the Merger, the SafeStitch stock price increased prior to the Merger closing date of September 3, 2013, generating additional goodwill. There may be impairment in the future and the impairment of goodwill will be assessed annually. The Company allocated $10,000 of the purchase price to identifiable intangible assets of trade names that met the separability and contractual legal criterion of ASC 805. The trade names will be amortized using the straight-line method over 5 years. The results of operations of SafeStitch have been included in the Company’s consolidated financial statements from the date of the Merger.
ALF-X Surgical Robotic System Acquisition [Member]
Acquisition of ALF-X Surgical Robotic System/ Closing of 2013 Merger and Financing Transaction	5. Acquisition of ALF-X Surgical Robotic System On September 21, 2015, the Company completed the strategic acquisition, through its wholly owned subsidiary TransEnterix International, from SOFAR, of all of the assets, employees and contracts related to the advanced robotic system for minimally invasive laparoscopic surgery known as the ALF-X System and changed the name of the acquired company from Vulcanos S.r.l. to TransEnterix Italia S.r.l. Under the terms of the Purchase Agreement, the consideration consisted of the issuance of 15,543,413 shares of the Company’s common stock (the “Securities Consideration”) and approximately $25 million U.S. Dollars and €27.5 million Euro in cash consideration (the “Cash Consideration”). The Securities Consideration was issued in full at the closing of the ALF-X Acquisition; the Cash Consideration was or will be paid in four tranches, as follows: (1) $25 million of the Cash Consideration was paid at closing; (2) The second tranche of the Cash Consideration (the “Second Tranche”) of €10 million shall be payable after the achievement of both of the following milestones (i) the earlier of approval from the FDA for the ALF-X System or December 31, 2016, and (ii) the Company having cash on hand of at least $50 million, or successfully completing a financing, raising at least $50 million in gross proceeds; with payment of simple interest at a rate of 9.0% per annum between the achievement of the first milestone event and the payment date; (3) The third tranche of the Cash Consideration (the “Third Tranche”) of €15 million shall be payable upon achievement of trailing revenues from sales or services contracts of the ALF-X System of at least €25 million over a calendar quarter; and (4) The fourth tranche of the Cash Consideration of €2.5 million shall be payable by December 31, 2016 as reimbursement for certain debt payments made by SOFAR under an existing SOFAR loan agreement. The Third Tranche will be payable even if the Second Tranche is not then payable. In addition, the Second Tranche and Third Tranche payments will be accelerated in the event that (i) the Company or TransEnterix International is acquired, (ii) the Company significantly reduces or suspends selling efforts of the ALF-X System, or (iii) the Company acquires a business that offers alternative products that are directly competitive with the ALF-X System. Under the Purchase Agreement, 10% of the Securities Consideration is being held in escrow to support SOFAR’s representations and warranties under the Purchase Agreement. The Company and SOFAR also entered into a Security Agreement, which provides that 10% of the membership interests of TransEnterix Italia have a lien placed thereon by and in favor of SOFAR to support the Company’s representations and warranties under the Purchase Agreement. The escrow period and security interest period are each twenty-four months after the closing of the ALF-X Acquisition. The Purchase Agreement contains customary representations and warranties of the parties and the parties have customary indemnification obligations, which are subject to certain limitations described further in the Purchase Agreement. In connection with the ALF-X Acquisition, the Company also entered into a Registration Rights Agreement, dated as of September 21, 2015, with SOFAR, pursuant to which the Company agreed to register the Securities Consideration shares for resale following the end of the lock-up periods described below. In connection with the ALF-X Acquisition, SOFAR entered into a Lock-Up Agreement with the Company pursuant to which SOFAR agreed, subject to certain exceptions, not to sell, transfer or otherwise convey any of the Securities Consideration for one year following the Closing Date. The Lock-up Agreement provides that SOFAR may sell, transfer or convey: (i) no more than 50% of the Securities Consideration during the period commencing on the one-year anniversary of the Closing Date and ending on the eighteen-month anniversary of the Closing Date; and (ii) no more than 75% of the Securities Consideration during the period commencing on the eighteen-month anniversary of the Closing Date and ending on the two-year anniversary of the Closing Date. The restrictions on transfer contained in the Lock-up Agreement cease to apply to the Securities Consideration following the second anniversary of the Closing Date, or earlier upon certain other conditions. The ALF-X Acquisition was accounted for as a business combination utilizing the methodology prescribed in ASC 805. The purchase price for the ALF-X Acquisition has been allocated to the assets acquired and liabilities assumed based on their estimated fair values. The purchase price allocation presented herein is preliminary. The final purchase price allocation will be determined after completion of an analysis to determine the fair value of all assets acquired and liabilities assumed, but in no event later than one year following completion of the ALF-X Acquisition. Accordingly, the final acquisition accounting adjustments could differ materially from the preliminary amounts presented herein. Any increase or decrease in the fair value of the assets acquired and liabilities assumed, as compared to the information shown herein, could also change the portion of purchase price allocated to goodwill, and could impact the operating results of the Company following the acquisition due to differences in purchase price allocation, depreciation and amortization related to some of these assets and liabilities. The ALF-X Acquisition-date fair value of the consideration is as follows (in thousands, except for per share amounts): Common shares issued 15,543 Closing price per share $ 2.81 $ 43,677 Cash consideration 25,000 Contingent consideration 24,300 Total consideration $ 92,977 The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed on September 21, 2015, the date of acquisition (in thousands): Accounts receivable $ 78 Inventories 3,200 Current deferred tax asset 351 Other current assets 4,180 Property and equipment 1,384 Intellectual property 62,500 In-process research and development 22,300 Goodwill 22,315 Total assets acquired $ 116,308 Accounts payable and other liabilities 1,915 Long-term deferred tax liabilities 21,416 Net assets acquired $ 92,977 The Company allocated $62.5 million of the preliminary purchase price to identifiable intangible assets of intellectual property that met the separability and contractual legal criterion of ASC 805. The intellectual property will be amortized using the straight-line method over 7 years. IPR&D is principally the estimated fair value of the ALF-X System technology which had not reached commercial technological feasibility nor had alternative future use at the time of the acquisition and therefore the Company considered IPR&D, with assigned values to be allocated among the various IPR&D assets acquired. Goodwill is calculated as the difference between the acquisition-date fair value of the consideration transferred and the fair values of the assets acquired and liabilities assumed. The goodwill resulting from these acquisitions arises largely from synergies expected from combining the operations of TransEnterix Italia with the Company’s existing operations. The goodwill is not deductible for income tax purposes. All legal, consulting and other costs related to the acquisition, aggregating approximately $4.0 million, have been expensed as incurred and are included in operating expenses in the Company’s consolidated statements of operations. The results of operations for TransEnterix Italia are included in the Company’s consolidated statements of operations for the period from the September 21, 2015 acquisition date to September 30, 2015. The Company has no revenues and incurred $262,000 in net losses from September 21, 2015 through September 30, 2015 associated with the operations of TransEnterix Italia. The following unaudited pro forma information presents the combined results of operations for the three and nine months ended September 30, 2015 and 2014, as if we had completed the ALF-X Acquisitions at the beginning of fiscal 2014. The pro forma financial information is provided for comparative purposes only and is not necessarily indicative of what actual results would have been had the acquisition occurred on the date indicated, nor does it give effect to synergies, cost savings, fair market value adjustments, immaterial amortization expense and other changes expected to result from the acquisition. Accordingly, the pro forma financial results do not purport to be indicative of consolidated results of operations as of the date hereof, for any period ended on the date hereof, or for any other future date or period. The pro forma consolidated financial information has been calculated after applying the Company’s accounting policies and includes adjustments for transaction-related costs and amortization of intellectual property. Three Months Ended Nine Months Ended 2015 2014 2015 2014 (In thousands) (In thousands) Revenue $ 77 $ 61 $ 77 $ 267 Net loss 12,597 14,575 38,058 38,869 Net loss per share $ 0.13 $ 0.19 $ 0.43 $ 0.53

Cash, Cash Equivalents, Restric

Cash, Cash Equivalents, Restricted Cash and Short-Term Investments	9 Months Ended
	Sep. 30, 2015
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents, Restricted Cash and Short-Term Investments	6. Cash, Cash Equivalents, Restricted Cash and Short-Term Investments The Company considers all highly liquid investments with original maturities of 90 days or less at the time of purchase to be cash equivalents and investments with original maturities of between 91 days and one year to be short-term investments. In order to manage exposure to credit risk, the Company invests in high-quality investments rated at least A2 by Moody’s Investors Service or A by Standard & Poor. Restricted cash, consisting of a money market account used as collateral securing a letter of credit under the terms of the corporate office operating lease that commenced in 2010 and expired in April 2015, was $0 and $250,000 as of September 30, 2015 and December 31, 2014, respectively. The Company held no investments at September 30, 2015 and December 31, 2014 as it sold all its investment securities during 2014. There were no realized gains or losses for the nine months ended September 30, 2015 or 2014. Cash, cash equivalents and restricted cash consist of the following: September 30, (In thousands) (unaudited) Cash $ 874 Money market 52,019 Total cash and cash equivalents 52,893 Total restricted cash $ — Total $ 52,893

Fair Value

Fair Value	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value	7. Fair Value The Company held certain assets and liabilities that are required to be measured at fair value on a recurring basis. These assets and liabilities include available for sale securities classified as cash equivalents and contingent consideration. ASC 820-10 (“Fair Value Measurement Disclosure”) requires the valuation using a three-tiered approach, which requires that fair value measurements be classified and disclosed in one of three tiers. These tiers are: Level 1, defined as quoted prices in active markets for identical assets or liabilities; Level 2, defined as valuations based on observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable input data; and Level 3, defined as valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants. For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data and therefore, are based primarily upon estimates, are often calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, the results cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique, and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the results of current or future values. The Company utilizes fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. As prescribed by U.S. GAAP, the Company groups assets and liabilities at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. An adjustment to the pricing method used within either Level 1 or Level 2 inputs could generate a fair value measurement that effectively falls in a lower level in the hierarchy. The determination of where an asset or liability falls in the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures and based on various factors, it is possible that an asset or liability may be classified differently from period to period. However, the Company expects changes in classifications between levels will be rare. The carrying values of accounts receivable, inventories, interest receivable, accounts payable, and certain accrued expenses at September 30, 2015 and December 31, 2014, approximate their fair values due to the short-term nature of these items. The Company’s notes payable balance also approximates fair value as of September 30, 2015 and December 31, 2014. The following are the major categories of assets measured at fair value on a recurring basis as of September 30, 2015 and December 31, 2014, using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3): September 30, 2015 (In thousands) (unaudited) Description Quoted Prices in Significant Other Significant Total Assets measured at fair value Cash and Cash Equivalents $ 52,893 $ — $ — $ 52,893 Total Assets measured at fair value $ 52,893 $ — $ — $ 52,893 Liabilities measured at fair value Contingent consideration $ — $ — $ 24,300 $ 24,300 Total liabilities measured at fair value $ — $ — $ 24,300 $ 24,300 December 31, 2014 (In thousands) Description Quoted Prices in Significant Other Significant Total Assets measured at fair value Cash and Cash Equivalents $ 34,766 $ — $ — $ 34,766 Restricted Cash 250 — — 250 Total Assets measured at fair value $ 35,016 $ — $ — $ 35,016 The Company’s financial liabilities consisted of contingent consideration potentially payable to SOFAR related to the ALF-X acquisition in September 2015 (Note 5). This liability is reported as Level 3 as estimated fair value of the contingent consideration related to the acquisition requires significant management judgment or estimation and is calculated using the income approach, using various revenue and cost assumptions and applying a probability to each outcome. There was no change in the fair value of the contingent consideration from September 21, 2015, the date of the ALF-X Acquisition, to September 30, 2015. The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements classified in Level 3 as of September 30, 2015: Fair Value at Significant Unobservable Input Weighted Average Contingent consideration $ 24,300 Probability weighted income approach Milestone dates 2016 to 2017 Discount rate 7.5% to 9.0% 100% The following table summarizes the change in fair value, as determined by Level 3 inputs, of the contingent consideration for the nine months ended September 30, 2015: September 30, (In thousands) (unaudited) Beginning balance $ — Additions 24,300 Change in fair value — Ending balance $ 24,300

Inventories

Inventories	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Inventories	8. Inventories The components of inventories are as follows: September 30, (In thousands) (unaudited) Finished goods $ 3,185 Raw materials 250 Ending balance $ 3,435

Goodwill, In-Process Research a

Goodwill, In-Process Research and Development and Intellectual Property	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, In-Process Research and Development and Intellectual Property	9. Goodwill, In-Process Research and Development and Intellectual Property Goodwill Goodwill has been recorded in connection with the Merger, as discussed in Note 15, and the ALF-X Acquisition, as discussed in Note 5. The carrying value of goodwill and the change in the balance for the nine months ended September 30, 2015 is as follows: September 30, (In thousands) (unaudited) Beginning balance $ 93,842 Additions 22,315 Foreign currency translation impact (103 ) Ending balance $ 116,054 The Company has no accumulated impairment losses on goodwill. In-Process Research and Development As described in Note 5, on September 21, 2015, the Company acquired all of the assets related to the ALF-X System and recorded $22.3 million of IPR&D. The estimated fair value of the IPR&D was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flows were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the acquisition date and the time and resources needed to complete development. The Company used a discount rate of 50% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions. The carrying value of the Company’s IPR&D assets and the change in the balance for the nine months ended September 30, 2015 is as follows: September 30, (In thousands) (unaudited) Beginning balance $ — Additions 22,300 Foreign currency translation impact (103 ) Ending balance $ 22,197 Intellectual Property As described in Note 5, on September 21, 2015, the Company acquired all of the assets related to the ALF-X System and recorded $62.5 million of intellectual property. The estimated fair value of the intellectual property was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flows were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the acquisition date and the time and resources needed to complete development. The Company used a discount rate of 45% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions. The carrying value of the Company’s intellectual property and the change in the balance for the nine months ended September 30, 2015 is as follows: September 30, 2015 (In thousands) (unaudited) Beginning balance $ 5,000 Additions 62,500 Foreign currency translation impact (286 ) Ending balance 67,214 Amortization of intellectual property (3,348 ) Total intellectual property $ 63,866

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2015
Text Block [Abstract]
Accrued Expenses	10. Accrued Expenses The following table presents the components of accrued expenses: September 30, 2015 December 31, (In thousands) (unaudited) Taxes and other assessments $ 3,023 $ 189 Compensation and benefits 1,713 1,036 Legal and professional fees 594 145 Consulting and other vendors 324 208 Interest and final payment fee 220 131 Deferred rent 230 46 Other 56 14 Total accrued expenses $ 6,160 $ 1,769

Related-Person Transactions

Related-Person Transactions	9 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related-Person Transactions	11. Related-Person Transactions Synecor, LLC and its shareholders and officers collectively owned approximately 6% and 9% of the Company’s common stock at September 30, 2015 and 2014, respectively. Various research and development services are purchased from Synecor LLC and its wholly owned subsidiary Synchrony Labs LLC pursuant to arms’ length terms approved by the Audit Committee and totaled approximately $434,000 and $15,000 for the nine months ended September 30, 2015 and 2014, respectively.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Notes Payable	12. Notes Payable On January 17, 2012, TransEnterix Surgical entered into a loan and security agreement with Silicon Valley Bank and Oxford Finance LLC (the “Lenders”). The terms of the Original Loan Agreement provided for two term loans in aggregate of $10,000,000 comprised of a $4,000,000 term loan and a $6,000,000 term loan. In connection with the Merger, the Company assumed and became the borrower under TransEnterix Surgical’s Original Loan Agreement, and agreed to amendments to the Original Loan Agreement, dated as of September 3, 2013 and October 31, 2013, respectively. The Original Loan Agreement had a maturity date of January 1, 2016 and a fixed interest rate of 8.75% per annum. As of September 26, 2014, the outstanding principal amount of the Original Loan Agreement was $5,604,000. On September 26, 2014, the Company entered into the Amended and Restated Loan Agreement with the Lenders. Under the Amended and Restated Loan Agreement, the Lenders agreed to make certain term loans (the “Amended and Restated Term Loans”) in an aggregate principal amount of up to $25,000,000. The first tranche of the Amended and Restated Term Loans increased the Company’s borrowings at September 26, 2014 from $5,604,000 to $10,000,000. The Amended and Restated Term Loans allowed for interest-only payment at 7.5% per annum through October 31, 2015 and a maturity date of April 1, 2018. On August 14, 2015, the Company entered into the First Amendment to the Amended and Restated Loan Agreement (the “First Amendment”) with the Lenders. The first tranche of the First Amendment increased the Company’s borrowings at August 14, 2015 from $10,000,000 to $20,000,000. A second tranche of $10,000,000, is available to the Company upon recognition of at least $10,000,000 of trailing six-month revenues from the SurgiBot System and SurgiBot-related products no later than March 31, 2017. The First Amendment allowed for interest-only payments at 7.5% per annum through April 30, 2016 and a maturity date of October 1, 2018. On September 18, 2015, in connection with entry into the Purchase Agreement with SOFAR S.p.A. (see Note 5 for a description of the related transactions), the Company and the Lenders entered into the Consent and Second Amendment to Amended and Restated Loan Agreement (the “Second Amendment”). The Second Amendment modified the period in which the Company can make interest-only payments at 7.5% per annum on the term loans until January 31, 2016. The interest-only period could be extended to July 1, 2016 if the Company completes an offering of its equity securities above $40,000,000 prior to January 31, 2016. The interest-only period could be further extended to January 1, 2017 upon obtaining 510(k) clearance from the FDA on its SurgiBot System by June 30, 2016. The Second Amendment has a maturity date of July 1, 2018 without the interest-only extensions, December 1, 2018 with the first interest-only extension, and June 1, 2019 with both interest-only extensions. In connection with the entry into the loan agreements, the Company became obligated to pay final payment and facility fees. The final payment fee obligation paid under the Original Loan Agreement at 3.33% was $333,000 and the facility fee payment was $75,000. The final payment fee obligation paid under the Amended and Restated Loan Agreement at 5.45% was $165,920 and the facility fee was $90,000. The facility fee paid under the First Amendment was $90,000. The final payment fee obligation payable under the Second Amendment is 6.5% of the original principal amount of each term loan without the interest only extension and 8.0% with both interest-only extensions. In addition, in connection with the borrowings, the Company issued warrants to the Lenders to purchase shares of the Company’s common stock amounting to 279,588 warrants under the Original Loan Agreement, 38,324 warrants under the Amended and Restated Loan Agreement and 112,903 under the First Amendment. Additional warrants will be issued if additional tranche term loans are made. The warrants expire seven years from their respective issue date. The Amended and Restated Loan Agreement, as amended, is secured by a security interest in all assets of the Company and its current and future U.S. subsidiaries, including a security interest in intellectual property proceeds, but excluding a current security interest in intellectual property. The Amended and Restated Loan Agreement contains customary representations (tested on a continual basis) and covenants that, subject to exceptions, restrict the Company’s ability to do the following things: declare dividends or redeem or repurchase equity interests; incur additional liens; make loans and investments; incur additional indebtedness; engage in mergers, acquisitions, and asset sales; transact with affiliates; undergo a change in control; add or change business locations; and engage in businesses that are not related to its existing business. Further, under the Second Amendment, the Lenders consented to the formation of TransEnterix International, the entry of the Company into the Purchase Agreement and other transaction documents, and the name change of TransEnterix Italia. The Company agreed to pledge 100% of the common stock of the TransEnterix International as additional security for the borrowings under the Amended and Restated Loan Agreement, as amended. The Second Amendment added a provision permitting the Company to transfer designated amounts to TransEnterix Italia during the term of the Amended and Restated Loan Agreement. In accordance with ASC 470-50 Debt – Modifications and Extinguishments, In accordance with ASC 470-50 Debt – Modifications and Extinguishments As of September 30, 2015 future principal payments under the Company’s notes payable agreements are as follows: Years ending December 31, (In thousands) 2016 $ 6,903 2017 8,090 2018 5,007 Total $ 20,000

Warrants

Warrants	9 Months Ended
	Sep. 30, 2015
Text Block [Abstract]
Warrants	13. Warrants On August 14, 2015, in connection with the First Amendment and the first tranche borrowings, the Company issued 112,903 common stock warrants to the Lenders to purchase shares of the Company’s common stock, with an exercise price of $3.10 per share. Additional common stock warrants will be issued if additional tranche term loans are made under the Amended and Restated Loan Agreement, as amended. The warrants expire seven years from their respective issue date. The Company concluded that the warrants are considered equity instruments. The warrants were recognized at the relative fair value on the issuance date as a debt discount and will be amortized using the effective interest method from issuance to the maturity of the note. None of these warrants were exercised during the nine months ended September 30, 2015.

Controlled Equity Offering and

Controlled Equity Offering and Public Offering of Common Stock	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Controlled Equity Offering and Public Offering of Common Stock	14. Controlled Equity Offering and Public Offering of Common Stock On June 11, 2015, the Company sold 16,666,667 shares of common stock at a public offering price of $3.00 per share for aggregate gross proceeds of $50 million in an underwritten firm commitment public offering. Net proceeds after issuance costs were $46.4 million. The closing of the public offering occurred on June 17, 2015. The Company granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 2,500,000 shares of Common Stock. On July 10, 2015, the underwriters exercised a portion of their option to acquire an additional 2,075,000 shares at the public offering price of $3.00 per share for aggregate additional gross proceeds of $6.2 million. Net proceeds after issuance costs were $5.8 million. The purchase of the option shares closed on July 15, 2015. Total proceeds (including the option) were $52.2 million, net of issuance costs of $4.0 million. The common stock was offered and sold pursuant to the Shelf Registration Statement filed in November 2014 (the “November 2014 Shelf Registration Statement”), which was declared effective on December 19, 2014. The November 2014 Shelf Registration Statement allowed the Company to raise up to $100.0 million through the sale of debt securities, common stock, preferred stock, warrants, or any combination thereof. On February 20, 2015, the Company entered into a Controlled Equity Offering SM The following table summarizes the total sales under the Sales Agreement for the periods indicated (in thousands, except per share amounts): Nine Months Ended September 30, Total shares of common stock sold 2,014.3 Average price per share $ 3.25 Gross proceeds $ 6,546 Commissions earned by Cantor $ 197 Other issuance costs $ 259 On April 14, 2014, the Company sold 12,500,000 shares of common stock at a public offering price of $4.00 per share for aggregate gross proceeds of $50.0 million in an underwritten firm commitment public offering. Certain of the Company’s existing stockholders that are affiliated with certain of the Company’s directors purchased $10.0 million of common stock in the public offering. The closing of the public offering occurred on April 21, 2014. The Company granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 1,875,000 shares of Common Stock to cover over-allotments. On April 30, 2014, the underwriters exercised a portion of their over-allotment option to acquire an additional 1,610,000 shares at the public offering price of $4.00 per share for aggregate additional gross proceeds of $6.4 million. The purchase of the over-allotment shares closed on May 5, 2014. Total proceeds were $52.4 million, net of issuance costs of $4.0 million. The common stock was offered and sold pursuant to the Shelf Registration Statement filed in January 2014 (the “January 2014 Shelf Registration Statement”), which was declared effective on April 2, 2014. The January 2014 Shelf Registration Statement allowed the Company to raise up to $100.0 million through the sale of debt securities, common stock, preferred stock, warrants, or any combination thereof.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Contingent Consideration As discussed in Note 5, in September 2015, the Company completed the ALF-X Acquisition using a combination of cash, stock and potential post-acquisition milestone payments. These milestone payments may be payable in the future, depending on the achievement of certain regulatory and commercial milestones. The maximum amount of the aggregate milestone payments could be €27.5 million. As of September 30, 2015, the fair value of the contingent consideration was $24.3 million. License and Supply Agreements As discussed in Note 5, in September 2015, the Company completed the ALF-X Acquisition. As part of this transaction, the Company assumed certain license and supply agreements. Commitments under these agreements amount to approximately $250,000 in 2015, $850,000 in 2016, $950,000 in 2017, $675,000 in 2018 and $3.4 million thereafter until termination in 2027.

Segment and Enterprise Wide Dis

Segment and Enterprise Wide Disclosures	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Segment and Enterprise Wide Disclosures	17. Segment and Enterprise Wide Disclosures The Company operates in one business segment—the research, development and sale of medical device robotics to improve minimally invasive surgery. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. Approximately 57% of the Company’s total consolidated assets are located within the U.S. as of September 30, 2015. The remaining assets are mostly located in Europe and are primarily related to the Company’s ALF-X facility in Italy, and include goodwill, intellectual property, in-process research and development and inventory of $115.6 million at September 30, 2015, associated with the ALF-X Acquisition in September 2015. Total assets outside of the U.S. excluding goodwill amounted to 35% of total consolidated assets at September 30, 2015. There were no international sales (sales outside the U.S.) during the nine months ended September 30, 2015 and 2014, respectively.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The Company has prepared the accompanying unaudited consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements are unaudited and should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on February 20, 2015. The accompanying unaudited interim consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) which are, in the opinion of the Company’s management, necessary for a fair statement of the Company’s consolidated financial position, results of operations and cash flows for the periods presented. These principles require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The principal estimates relate to inventory valuation, stock-based compensation, accrued expenses and income tax valuation. Actual results could differ from those estimates. The year-end balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. For a description of our critical accounting policies and estimates, please refer to the “Critical Accounting Policies and Estimates” section of the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on February 20, 2015. There have been no material changes in any of our accounting policies since December 31, 2014.
Going Concern	Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis. The Company has accumulated a deficit of approximately $169.3 million as of September 30, 2015, a net loss of approximately $33.4 million for the nine months ended September 30, 2015, and has not generated significant revenue or positive cash flows from operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty. To meet its capital needs, the Company is considering multiple alternatives, including, but not limited to, additional equity financings, debt financings and other funding transactions. There can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. If the Company is unable to obtain the necessary capital, it will need to pursue a plan to license or sell its assets, seek to be acquired by another entity and/or cease operations.
Consolidation	Consolidation The accompanying consolidated financial statements include the accounts of the Company and its direct and indirect wholly owned subsidiaries, SafeStitch LLC, TransEnterix Surgical, Inc., TransEnterix International, Inc. and TransEnterix Italia. All inter-company accounts and transactions have been eliminated in consolidation.
Reverse Merger	Reverse Merger On September 3, 2013, TransEnterix Surgical and SafeStitch, consummated the Merger whereby TransEnterix Surgical merged with a merger subsidiary of SafeStitch, with TransEnterix Surgical as the surviving entity in the Merger. As a result of the Merger, TransEnterix Surgical became a wholly owned subsidiary of SafeStitch. On December 6, 2013, SafeStitch changed its corporate name to TransEnterix, Inc. The Reverse Merger has been accounted for as a reverse acquisition under which TransEnterix Surgical was considered the acquirer of SafeStitch. As such, the financial statements of TransEnterix Surgical are treated as the historical financial statements of the combined company, with the results of SafeStitch being included from September 3, 2013. As a result of the Reverse Merger with SafeStitch, historical common stock amounts and additional paid in capital have been retroactively adjusted using an Exchange Ratio of 1.1533.
Reverse Stock Split	Reverse Stock Split On March 31, 2014, the Company effectuated a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1 for 5 (the “Reverse Stock Split”). As a result of the Reverse Stock Split, the Company’s issued and outstanding stock decreased from 244,276,923 to 48,855,255 shares of common stock, all with a par value of $0.001. All information related to common stock, stock options, restricted stock units, warrants and earnings per share for prior periods has been retroactively adjusted to give effect to the Reverse Stock Split, except for the reference to the Merger Exchange Ratio of 1.1533.
Inventories	Inventories Inventories are stated at the lower of cost or market. Cost is based on the first in, first out method. The Company records reserves, when necessary, to reduce the carrying value of inventory to its net realizable value. Management considers forecast demand in relation to the inventory on hand, competitiveness of product offerings, market conditions and product life cycles when determining excess and obsolescence and net realizable value adjustments. At the point of loss recognition, a new, lower-cost basis for that inventory is established, and any subsequent improvements in facts and circumstances do not result in the restoration or increase in that newly established cost basis.
Identifiable Intangible Assets and Goodwill	Identifiable Intangible Assets and Goodwill Identifiable intangible assets are recorded at cost, or when acquired as part of a business acquisition, at estimated fair value. Certain intangible assets are amortized over 7 to 10 years. Similar to tangible personal property and equipment, the Company periodically evaluates identifiable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. No impairment existed at September 30, 2015 or December 31, 2014. Indefinite-lived intangible assets, such as goodwill, are not amortized. The Company tests the carrying amounts of goodwill for recoverability on an annual basis at December 31st or when events or changes in circumstances indicate evidence of potential impairment exists, using a fair value based test. No impairment existed at September 30, 2015 or December 31, 2014.
In-Process Research and Development	In-Process Research and Development In-process research and development (“IPR&D”) assets represent the fair value assigned to technologies that are acquired, which at the time of acquisition have not reached technological feasibility and have no alternative future use. IPR&D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development projects. During the period that the IPR&D assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if the Company becomes aware of any events occurring or changes in circumstances that indicate that the fair value of the IPR&D assets are less than their carrying amounts. If and when development is complete, which generally occurs upon regulatory approval, and the Company is able to commercialize products associated with the IPR&D assets, these assets are then deemed definite-lived and are amortized based on their estimated useful lives at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&D assets, calculated as the excess of carrying value of the IPR&D assets over fair value.
Contingent Consideration	Contingent Consideration Contingent consideration is recorded as a liability and is the estimate of the fair value of potential milestone payments related to business acquisitions. Contingent consideration is measured at fair value using a discounted cash flow model utilizing significant unobservable inputs including the probability of achieving each of the potential milestones and an estimated discount rate associated with the risks of the expected cash flows attributable to the various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected timelines for achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The fair value of the contingent consideration at each reporting date is updated by reflecting the changes in fair value in our statement of operations.
Debt Issuance Costs	Debt Issuance Costs The Company capitalizes costs associated with the issuance of debt instruments and amortizes these costs to interest expense over the term of the related debt agreement using the effective yield amortization method. Unamortized debt issuance costs will be charged to operations when indebtedness under the related credit facility is repaid prior to maturity.
Translation of Foreign Currencies	Translation of Foreign Currencies The functional currency of the Company’s foreign subsidiary, TransEnterix Italia, is its local currency. The assets and liabilities of the Company’s foreign subsidiary are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at the average exchange rates prevailing during the period. The cumulative translation effect for a subsidiary using a functional currency other than the U.S. dollar is included in accumulated other comprehensive income or loss as a separate component of stockholders’ equity. The Company’s intercompany accounts are denominated in the functional currency of the foreign subsidiary. Gains and losses resulting from the remeasurement of intercompany receivables that the Company considers to be of a long-term investment nature are recorded as a cumulative translation adjustment in accumulated other comprehensive income or loss as a separate component of stockholders’ equity, while gains and losses resulting from the remeasurement of intercompany receivables from a foreign subsidiary for which the Company anticipates settlement in the foreseeable future are recorded in the consolidated statement of operations. The net gains and losses recorded in the consolidated statements of operations for the three and nine months ended September 30, 2015 were not significant.
Business Acquisitions	Business Acquisitions Business acquisitions are accounted for using the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) 805, “Business Combinations.” ASC 805 requires, among other things, that assets acquired and liabilities assumed be recognized at their fair values, as determined in accordance with ASC 820, “Fair Value Measurements,” as of the acquisition date. For certain assets and liabilities, book value approximates fair value. In addition, ASC 805 establishes that consideration transferred be measured at the closing date of the acquisition at the then-current market price, which may be different than the amount of consideration assumed in the pro forma financial statements. Under ASC 805, acquisition related costs (i.e., advisory, legal, valuation and other professional fees) and certain acquisition-related restructuring charges impacting the target company are expensed in the period in which the costs are incurred. The application of the acquisition method of accounting requires the Company to make estimates and assumptions related to the estimated fair values of net assets acquired. Significant judgments are used during this process, particularly with respect to intangible assets. Generally, intangible assets are amortized over their estimated useful lives. Goodwill and other indefinite-lived intangibles are not amortized, but are annually assessed for impairment. Therefore, the purchase price allocation to intangible assets and goodwill has a significant impact on future operating results.
Impact of Recently Issued Accounting Standards	Impact of Recently Issued Accounting Standards In September 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory
Reclassifications	Reclassifications As a result of a recent acquisition, certain financial statement captions have been added and we have reclassified certain prior-period amounts on our Consolidated Statement of Operations to conform to the presentation for the current period. Such reclassifications have no effect on previously reported total assets, liabilities, stockholders’ equity or net loss. As previously disclosed, in April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest

Acquisition of ALF-X Surgical24

Acquisition of ALF-X Surgical Robotic System/ Closing of 2013 Merger and Financing Transaction (Tables)	9 Months Ended
	Sep. 30, 2015
Schedule of Allocation of Purchase Price to Net Assets Acquired	The following table summarizes the allocation of the purchase price to the net assets acquired (in thousands): Cash and cash equivalents $ 597 Accounts receivable 54 Inventory 50 Other current assets 53 Property and equipment 185 Other long-term asset 2 Intangible assets 10 Goodwill 93,842 Total assets acquired $ 94,793 Accounts payable and other liabilities 642 Total purchase price $ 94,151
Schedule of Purchase Price	The following table summarizes the purchase price (in thousands): Common shares outstanding at the date of Merger 12,350 Closing price per share $ 7.60 $ 93,858 Cash consideration 293 Total purchase price $ 94,151
ALF-X Surgical Robotic System Acquisition [Member]
Schedule of Allocation of Purchase Price to Net Assets Acquired	The ALF-X Acquisition-date fair value of the consideration is as follows (in thousands, except for per share amounts): Common shares issued 15,543 Closing price per share $ 2.81 $ 43,677 Cash consideration 25,000 Contingent consideration 24,300 Total consideration $ 92,977
Schedule of Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed on September 21, 2015, the date of acquisition (in thousands): Accounts receivable $ 78 Inventories 3,200 Current deferred tax asset 351 Other current assets 4,180 Property and equipment 1,384 Intellectual property 62,500 In-process research and development 22,300 Goodwill 22,315 Total assets acquired $ 116,308 Accounts payable and other liabilities 1,915 Long-term deferred tax liabilities 21,416 Net assets acquired $ 92,977
Summary of Business Acquisition, ProForma Information	The pro forma consolidated financial information has been calculated after applying the Company’s accounting policies and includes adjustments for transaction-related costs and amortization of intellectual property. Three Months Ended Nine Months Ended 2015 2014 2015 2014 (In thousands) (In thousands) Revenue $ 77 $ 61 $ 77 $ 267 Net loss 12,597 14,575 38,058 38,869 Net loss per share $ 0.13 $ 0.19 $ 0.43 $ 0.53

Cash, Cash Equivalents, Restr25

Cash, Cash Equivalents, Restricted Cash and Short-Term Investments (Tables)	9 Months Ended
	Sep. 30, 2015
Cash and Cash Equivalents [Abstract]
Summary of Cash, Cash Equivalents and Restricted Cash	Cash, cash equivalents and restricted cash consist of the following: September 30, (In thousands) (unaudited) Cash $ 874 Money market 52,019 Total cash and cash equivalents 52,893 Total restricted cash $ — Total $ 52,893

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Summary of Assets Measured at Fair Value on Recurring Basis	The following are the major categories of assets measured at fair value on a recurring basis as of September 30, 2015 and December 31, 2014, using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3): September 30, 2015 (In thousands) (unaudited) Description Quoted Prices in Significant Other Significant Total Assets measured at fair value Cash and Cash Equivalents $ 52,893 $ — $ — $ 52,893 Total Assets measured at fair value $ 52,893 $ — $ — $ 52,893 Liabilities measured at fair value Contingent consideration $ — $ — $ 24,300 $ 24,300 Total liabilities measured at fair value $ — $ — $ 24,300 $ 24,300 December 31, 2014 (In thousands) Description Quoted Prices in Significant Other Significant Total Assets measured at fair value Cash and Cash Equivalents $ 34,766 $ — $ — $ 34,766 Restricted Cash 250 — — 250 Total Assets measured at fair value $ 35,016 $ — $ — $ 35,016
Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classified in Level 3	The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements classified in Level 3 as of September 30, 2015: Fair Value at Significant Unobservable Input Weighted Average Contingent consideration $ 24,300 Probability weighted income approach Milestone dates 2016 to 2017 Discount rate 7.5% to 9.0% 100%
Change in Fair Value of Contingent Consideration as Determined by Level 3 Inputs	The following table summarizes the change in fair value, as determined by Level 3 inputs, of the contingent consideration for the nine months ended September 30, 2015: September 30, (In thousands) (unaudited) Beginning balance $ — Additions 24,300 Change in fair value — Ending balance $ 24,300

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory	The components of inventories are as follows: September 30, (In thousands) (unaudited) Finished goods $ 3,185 Raw materials 250 Ending balance $ 3,435

Goodwill, In-Process Research28

Goodwill, In-Process Research and Development and Intellectual Property (Tables)	9 Months Ended
	Sep. 30, 2015
Carrying Value of Goodwill and Change in Balance	The carrying value of goodwill and the change in the balance for the nine months ended September 30, 2015 is as follows: September 30, (In thousands) (unaudited) Beginning balance $ 93,842 Additions 22,315 Foreign currency translation impact (103 ) Ending balance $ 116,054
In-Process Research and Development [Member]
Carrying Value of Company's Intangible Assets and Change in Balance	The carrying value of the Company’s IPR&D assets and the change in the balance for the nine months ended September 30, 2015 is as follows: September 30, (In thousands) (unaudited) Beginning balance $ — Additions 22,300 Foreign currency translation impact (103 ) Ending balance $ 22,197
Intellectual Property [Member]
Carrying Value of Company's Intangible Assets and Change in Balance	The carrying value of the Company’s intellectual property and the change in the balance for the nine months ended September 30, 2015 is as follows: September 30, 2015 (In thousands) (unaudited) Beginning balance $ 5,000 Additions 62,500 Foreign currency translation impact (286 ) Ending balance 67,214 Amortization of intellectual property (3,348 ) Total intellectual property $ 63,866

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2015
Text Block [Abstract]
Schedule of Accrued Expenses	The following table presents the components of accrued expenses: September 30, 2015 December 31, (In thousands) (unaudited) Taxes and other assessments $ 3,023 $ 189 Compensation and benefits 1,713 1,036 Legal and professional fees 594 145 Consulting and other vendors 324 208 Interest and final payment fee 220 131 Deferred rent 230 46 Other 56 14 Total accrued expenses $ 6,160 $ 1,769

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Summary of Notes Payable Agreements	As of September 30, 2015 future principal payments under the Company’s notes payable agreements are as follows: Years ending December 31, (In thousands) 2016 $ 6,903 2017 8,090 2018 5,007 Total $ 20,000

Controlled Equity Offering an31

Controlled Equity Offering and Public Offering of Common Stock (Tables)	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Schedule of Total Sales under Sales Agreement	The following table summarizes the total sales under the Sales Agreement for the periods indicated (in thousands, except per share amounts): Nine Months Ended September 30, Total shares of common stock sold 2,014.3 Average price per share $ 3.25 Gross proceeds $ 6,546 Commissions earned by Cantor $ 197 Other issuance costs $ 259

Organization and Capitalizati32

Organization and Capitalization - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2015Segmentshares	Dec. 31, 2014shares	Dec. 06, 2013$ / sharesshares
Organization and Capitalization [Line Items]
Common stock, shares authorized	750,000,000	750,000,000
Preferred stock, shares authorized			25,000,000
Preferred stock, par value (in dollars per share) | $ / shares			$ 0.01
Number of business segments | Segment	1
Minimum [Member]
Organization and Capitalization [Line Items]
Common stock, shares authorized			225,000,000
Maximum [Member]
Organization and Capitalization [Line Items]
Common stock, shares authorized			750,000,000

Summary of Significant Accoun33

Summary of Significant Accounting Policies - Additional Information (Detail)	Sep. 03, 2013$ / sharesshares	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)$ / sharesshares	Mar. 31, 2014$ / sharesshares	Mar. 30, 2014shares
Accounting Policies [Line Items]
Accumulated deficit		$ (169,285,000)		$ (169,285,000)		$ (135,916,000)
Net loss		$ (13,901,000)	$ (11,507,000)	$ (33,369,000)	$ (29,573,000)
Common stock, shares issued | shares		100,103,989		100,103,989		63,182,806	48,855,255	244,276,923
Common stock, shares outstanding | shares		100,102,816		100,102,816		63,182,806	48,855,255	244,276,923
Common stock, par value (in dollars per share) | $ / shares		$ 0.001		$ 0.001		$ 0.001	$ 0.001
Impairment charges				$ 0		$ 0
Debt issuance costs reclassified				$ 100,000
Maximum [Member]
Accounting Policies [Line Items]
Amortization period				10 years
Minimum [Member]
Accounting Policies [Line Items]
Amortization period				7 years
Safe Stitch Medical Inc [Member]
Accounting Policies [Line Items]
Exchange ratio	1.1533
Common stock, shares outstanding | shares	12,350,000
Common stock, par value (in dollars per share) | $ / shares	$ 0.001
Amortization period	5 years

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Estimated annual effective tax rate	2.85%	2.85%
Income tax benefit	$ (99,000)	$ (99,000)
Effective tax rate		0.297%	0.00%
Unrecognized tax benefits	$ 0	$ 0

Acquisition of ALF-X Surgical35

Acquisition of ALF-X Surgical Robotic System - Additional Information (Detail)	Sep. 30, 2015USD ($)	Sep. 21, 2015USD ($)shares	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 21, 2015EUR (€)	Dec. 31, 2014USD ($)
Business Acquisition [Line Items]
Securities consideration held in escrow percentage		10.00%
Escrow and security interest period		24 months
Intellectual property, net	$ 63,866,000		$ 63,866,000		$ 63,866,000			$ 2,241,000
Legal, consulting and other costs related to acquisition			4,003,000		4,003,000
Revenues				$ 61,000		$ 267,000
Net loss			$ (13,901,000)	$ (11,507,000)	$ (33,369,000)	$ (29,573,000)
Minimum [Member]
Business Acquisition [Line Items]
Amortization period					7 years
Maximum [Member]
Business Acquisition [Line Items]
Amortization period					10 years
ALF-X Surgical Robotic System Acquisition [Member]
Business Acquisition [Line Items]
Common shares issued | shares		15,543,413
Cash consideration		$ 25,000,000
Acquisition agreement, description					The Lock-up Agreement provides that SOFAR may sell, transfer or convey (i) no more than 50% of the Securities Consideration during the period commencing on the one-year anniversary of the Closing Date and ending on the eighteen-month anniversary of the Closing Date; and (ii) no more than 75% of the Securities Consideration during the period commencing on the eighteen-month anniversary of the Closing Date and ending on the two-year anniversary of the Closing Date.
Intellectual property, net		$ 62,500,000
Amortization period		7 years
ALF-X Surgical Robotic System Acquisition [Member] | Maximum [Member] | Ending on Eighteen Month Anniversary [Member]
Business Acquisition [Line Items]
Percentage of securities consideration		50.00%
ALF-X Surgical Robotic System Acquisition [Member] | Maximum [Member] | Ending on Two Year Anniversary [Member]
Business Acquisition [Line Items]
Percentage of securities consideration		75.00%
ALF-X Surgical Robotic System Acquisition [Member] | U.S. Dollars [Member]
Business Acquisition [Line Items]
Cash consideration		$ 25,000,000
ALF-X Surgical Robotic System Acquisition [Member] | Euro [Member]
Business Acquisition [Line Items]
Cash consideration payable | €							€ 27,500,000
ALF-X Surgical Robotic System Acquisition [Member] | First Tranche [Member]
Business Acquisition [Line Items]
Cash consideration		25,000,000
ALF-X Surgical Robotic System Acquisition [Member] | Second Tranche [Member]
Business Acquisition [Line Items]
Cash consideration payable | €							€ 10,000,000
Gross proceeds from financing		$ 50,000,000
Interest rate		9.00%					9.00%
ALF-X Surgical Robotic System Acquisition [Member] | Second Tranche [Member] | Minimum [Member]
Business Acquisition [Line Items]
Cash on hand		$ 50,000,000
ALF-X Surgical Robotic System Acquisition [Member] | Third Tranche [Member]
Business Acquisition [Line Items]
Cash consideration payable | €							€ 15,000,000
ALF-X Surgical Robotic System Acquisition [Member] | Third Tranche [Member] | Minimum [Member]
Business Acquisition [Line Items]
Target revenue to be achieved | €							25,000,000
ALF-X Surgical Robotic System Acquisition [Member] | Fourth Tranche [Member]
Business Acquisition [Line Items]
Cash consideration payable | €							€ 2,500,000
TransEnterix Italia [Member]
Business Acquisition [Line Items]
Membership interests percentage under Security agreement		10.00%					10.00%
Legal, consulting and other costs related to acquisition	4,000,000
Revenues	0
Net loss	$ 262,000

Acquisition of ALF-X Surgical36

Acquisition of ALF-X Surgical Robotic System - Summary of Fair Value Consideration (Detail) - USD ($) $ / shares in Units, $ in Thousands	Sep. 21, 2015	Sep. 30, 2015
Business Acquisition [Line Items]
Contingent consideration		$ 24,300
ALF-X Surgical Robotic System Acquisition [Member]
Business Acquisition [Line Items]
Common shares issued	15,543,413
Closing price per share	$ 2.81
Consideration share value	$ 43,677
Cash consideration	25,000
Contingent consideration	24,300	$ 24,300
Total purchase price	$ 92,977

Acquisition of ALF-X Surgical37

Acquisition of ALF-X Surgical Robotic System - Schedule of Estimated Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 21, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill	$ 116,054		$ 93,842
ALF-X Surgical Robotic System Acquisition [Member]
Business Acquisition [Line Items]
Accounts receivable		$ 78
Inventories		3,200
Current deferred tax asset		351
Other current assets		4,180
Property and equipment		1,384
Intellectual property		62,500
In-process research and development		22,300
Goodwill		22,315
Total assets acquired		116,308
Accounts payable and other liabilities		1,915
Long-term deferred tax liabilities		21,416
Net assets acquired		$ 92,977

Acquisition of ALF-X Surgical38

Acquisition of ALF-X Surgical Robotic System - Summary of Business Acquisition, ProForma Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Business Acquisition [Line Items]
Net loss per share	$ 0.13	$ 0.19	$ 0.43	$ 0.53
ALF-X Surgical Robotic System Acquisition [Member]
Business Acquisition [Line Items]
Revenue	$ 77	$ 61	$ 77	$ 267
Net loss	$ 12,597	$ 14,575	$ 38,058	$ 38,869

Cash and Cash Equivalents, Rest

Cash and Cash Equivalents, Restricted Cash and Short-Term Investments - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Cash and Cash Equivalents [Abstract]
Restricted cash	$ 0		$ 250,000
Investments	0		$ 0
Realized gains or losses	$ 0	$ 0

Cash and Cash Equivalents, Re40

Cash and Cash Equivalents, Restricted Cash and Short-Term Investments - Summary of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Cash and Cash Equivalents [Abstract]
Cash	$ 874
Money market	52,019
Total cash and cash equivalents	52,893	$ 34,766	$ 44,344	$ 10,014
Total restricted cash	0	250
Total	$ 52,893	$ 35,016

Fair Value - Summary of Assets

Fair Value - Summary of Assets Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Assets measured at fair value
Cash and cash equivalents	$ 52,893	$ 34,766	$ 44,344	$ 10,014
Restricted cash	0	250
Total Assets measured at fair value	52,893	35,016
Liabilities measured at fair value
Contingent consideration	24,300
Total liabilities measured at fair value	24,300
Fair Value, Inputs, Level 1 [Member]
Assets measured at fair value
Cash and cash equivalents	52,893	34,766
Restricted cash		250
Total Assets measured at fair value	52,893	$ 35,016
Fair Value, Inputs, Level 3 [Member]
Liabilities measured at fair value
Contingent consideration	24,300
Total liabilities measured at fair value	$ 24,300

Fair Value - Quantitative Infor

Fair Value - Quantitative Information about Inputs and Valuation Methodologies Used for Fair Value Measurements Classified in Level 3 (Detail) - USD ($) $ in Thousands	Sep. 21, 2015	Sep. 30, 2015
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration		$ 24,300
Fair Value, Inputs, Level 3 [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration		24,300
ALF-X Surgical Robotic System Acquisition [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration	$ 24,300	$ 24,300
ALF-X Surgical Robotic System Acquisition [Member] | Fair Value, Inputs, Level 3 [Member] | Contingent Consideration [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Probability of occurrence		100.00%
ALF-X Surgical Robotic System Acquisition [Member] | Fair Value, Inputs, Level 3 [Member] | Contingent Consideration [Member] | Minimum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Milestone dates		2,016
Discount rate		7.50%
ALF-X Surgical Robotic System Acquisition [Member] | Fair Value, Inputs, Level 3 [Member] | Contingent Consideration [Member] | Maximum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Milestone dates		2,017
Discount rate		9.00%
ALF-X Surgical Robotic System Acquisition [Member] | Fair Value, Inputs, Level 3 [Member] | Income Approach Valuation Technique [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration		$ 24,300

Fair Value - Change in Fair Val

Fair Value - Change in Fair Value of Contingent Consideration as Determined by Level 3 Inputs (Detail) - Fair Value, Inputs, Level 3 [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Additions	$ 24,300
Change in fair value	0
Ending balance	$ 24,300

Inventories - Schedule of Inven

Inventories - Schedule of Inventory (Detail) $ in Thousands	Sep. 30, 2015USD ($)
Inventory Disclosure [Abstract]
Finished goods	$ 3,185
Raw materials	250
Ending balance	$ 3,435

Goodwill, In-Process Research45

Goodwill, In-Process Research and Development and Intangible Assets - Carrying Value of Goodwill and Change in Balance (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning balance	$ 93,842
Additions	22,315
Foreign currency translation impact	(103)
Ending balance	$ 116,054

Goodwill, In-Process Research46

Goodwill, In-Process Research and Development and Intangible Assets - Additional Information (Detail) - USD ($)	Sep. 21, 2015	Sep. 30, 2015
Goodwill And Intangible Assets [Line Items]
Accumulated impairment losses on goodwill		$ 0
In-Process Research and Development [Member]
Goodwill And Intangible Assets [Line Items]
In-process research and development		$ 22,197,000
Discount rate	50.00%
Intellectual Property [Member]
Goodwill And Intangible Assets [Line Items]
Discount rate	45.00%
ALF-X Surgical Robotic System Acquisition [Member]
Goodwill And Intangible Assets [Line Items]
Intellectual property	$ 62,500,000
ALF-X Surgical Robotic System Acquisition [Member] | In-Process Research and Development [Member]
Goodwill And Intangible Assets [Line Items]
In-process research and development	$ 22,300,000

Goodwill, In-Process Research47

Goodwill, In-Process Research and Development and Intangible Assets - Carrying Value of Company's IPR&D Assets and Change in Balance (Detail) - In-Process Research and Development [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Finite-Lived Intangible Assets [Line Items]
Additions	$ 22,300
Foreign currency translation impact	(103)
Ending balance	$ 22,197

Goodwill, In-Process Research48

Goodwill, In-Process Research and Development and Intangible Assets - Schedule of Carrying Value of Company's Intellectual Property and Change in Balance (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Intangible Assets By Major Class [Line Items]
Beginning balance	$ 2,241
Ending balance	63,866
Intellectual Property [Member]
Intangible Assets By Major Class [Line Items]
Beginning balance	5,000
Additions	62,500
Foreign currency translation impact	(286)
Ending balance	67,214
Amortization of intellectual property	(3,348)
Total intellectual property	$ 63,866

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Accrued Liabilities, Current [Abstract]
Taxes and other assessments	$ 3,023	$ 189
Compensation and benefits	1,713	1,036
Legal and professional fees	594	145
Consulting and other vendors	324	208
Interest and final payment fee	220	131
Deferred rent	230	46
Other	56	14
Total accrued expenses	$ 6,160	$ 1,769

Related-Person Transactions - A

Related-Person Transactions - Additional Information (Detail) - Synecor, LLC [Member] - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Related Party Transaction [Line Items]
Payments to Acquire in Process Research and Development	$ 434,000	$ 15,000
Officer [Member] | Common Stock [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	6.00%	9.00%

Notes Payable - Additional Info

Notes Payable - Additional Information (Detail) - USD ($)	Sep. 18, 2015	Aug. 14, 2015	Sep. 26, 2014	Jan. 17, 2012	Sep. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Debt discount liability, facility fee			$ 75,000
Warrants expiration period			7 years
Approximated Amount of debt discount			$ 129,000
Fair value of warrants on the issue date			54,000
Debt discount liability, legal fees			30,000
Other Current Assets [Member]
Debt Instrument [Line Items]
Decrease in retrospectively revision from prior periods						$ 49,000
Other Long Term Assets [Member]
Debt Instrument [Line Items]
Decrease in retrospectively revision from prior periods						51,000
Notes Payable Less Current Portion, Net of Debt Discount [Member]
Debt Instrument [Line Items]
Decrease in retrospectively revision from prior periods						$ 100,000
First Amended and Restated Loan Agreement [Member]
Debt Instrument [Line Items]
Interest only payment percentage		7.50%
Maturity date of the term loans		Oct. 1, 2018
Debt discount liability, facility fee					$ 90,000
Issue of warrants to purchase shares of company's common stock					112,903
First Amended and Restated Loan Agreement [Member] | SurgiBot [Member]
Debt Instrument [Line Items]
Trailing six-month revenues recognition		$ 10,000,000
First Amended and Restated Loan Agreement [Member] | First Tranche [Member] | Minimum [Member]
Debt Instrument [Line Items]
Amount of borrowing under agreement		10,000,000
First Amended and Restated Loan Agreement [Member] | First Tranche [Member] | Maximum [Member]
Debt Instrument [Line Items]
Amount of borrowing under agreement		20,000,000
First Amended and Restated Loan Agreement [Member] | Second Tranche [Member]
Debt Instrument [Line Items]
Amount of borrowing under agreement		$ 10,000,000
Second Amended and Restated Loan Agreement [Member]
Debt Instrument [Line Items]
Interest only payment percentage	7.50%
Amount of equity securities offering					$ 40,000,000
Second Amended and Restated Loan Agreement [Member] | Without Interest- Only Extension [Member]
Debt Instrument [Line Items]
Maturity date of the term loans	Jul. 1, 2018
Debt instrument, redemption price percentage					6.50%
Second Amended and Restated Loan Agreement [Member] | First Interest- Only Extension [Member]
Debt Instrument [Line Items]
Maturity date of the term loans	Dec. 1, 2018
Second Amended and Restated Loan Agreement [Member] | With Interest-Only Extension [Member]
Debt Instrument [Line Items]
Maturity date of the term loans	Jun. 1, 2019
Debt instrument, redemption price percentage					8.00%
Amended and Restated Loan Agreement [Member]
Debt Instrument [Line Items]
Term loan aggregate principal amount			$ 25,000,000
Interest only payment percentage			7.50%
Maturity date of the term loans			Apr. 1, 2018
Debt instrument, redemption price percentage					5.45%
Debt Instrument, redemption price amount					$ 165,920
Debt discount liability, facility fee					$ 90,000
Issue of warrants to purchase shares of company's common stock					38,324
Warrants expiration period					7 years
Percentage of common stock pledged					100.00%
Amended and Restated Loan Agreement [Member] | First Tranche [Member] | Minimum [Member]
Debt Instrument [Line Items]
Amount of borrowing under agreement			$ 5,604,000
Amended and Restated Loan Agreement [Member] | First Tranche [Member] | Maximum [Member]
Debt Instrument [Line Items]
Amount of borrowing under agreement			10,000,000
Notes Payable [Member]
Debt Instrument [Line Items]
Debt discount liability, facility fee					$ 90,000
Debt discount liability, legal fees					23,000
Debt discount liability, discount					210,000
Debt discount liability, fair value of warrant					$ 97,000
Loan and Security Agreement [Member]
Debt Instrument [Line Items]
Note issuance date				Jan. 17, 2012
Issuance of promissory note as part of merger transaction				$ 10,000,000
Maturity date				Jan. 1, 2016
Term loan fixed interest rate				8.75%
Outstanding principal amount of the original loan agreement			$ 5,604,000
Debt instrument, redemption price percentage			3.33%
Debt Instrument, redemption price amount			$ 333,000
Debt discount liability, facility fee			$ 75,000
Issue of warrants to purchase shares of company's common stock				279,588
Loan and Security Agreement [Member] | Term A Loan [Member]
Debt Instrument [Line Items]
Issuance of promissory note as part of merger transaction				$ 4,000,000
Loan and Security Agreement [Member] | Term B Loan [Member]
Debt Instrument [Line Items]
Issuance of promissory note as part of merger transaction				$ 6,000,000

Notes Payable - Summary of Note

Notes Payable - Summary of Notes Payable Agreements (Detail) - Notes Payable, Other Payables [Member] $ in Thousands	Sep. 30, 2015USD ($)
Debt Instrument [Line Items]
2,016	$ 6,903
2,017	8,090
2,018	5,007
Total	$ 20,000

Warrants - Additional Informati

Warrants - Additional Information (Detail) - $ / shares	Aug. 14, 2015	Sep. 26, 2014	Sep. 30, 2015
Class of Warrant or Right [Line Items]
Warrant, expiration period		7 years
Amended and Restated Loan Agreement [Member]
Class of Warrant or Right [Line Items]
Common stock warrants issued	112,903
Warrants exercised			0
Warrant, expiration period			7 years
Warrants, exercise price	$ 3.10

Controlled Equity Offering an54

Controlled Equity Offering and Public Offering of Common Stock - Additional Information (Detail) - USD ($)	Jul. 10, 2015	Jun. 11, 2015	Feb. 20, 2015	Apr. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Apr. 14, 2014
Stockholders Equity Common Stock [Line Items]
Common stock to be sold, shares		16,666,667					12,500,000
Public offering price	$ 3	$ 3		$ 4			$ 4
Expected aggregate gross proceeds		$ 50,000,000					$ 50,000,000
Over-allotment option, shares to be issued to underwriters		2,500,000					1,875,000
Shares issued from option exercise by underwriters	2,075,000			1,610,000
Additional proceeds from exercise of option by underwriters	$ 6,200,000			$ 6,400,000
Proceeds from issuance of common stock, net of issuance costs	$ 5,800,000	$ 46,400,000		52,400,000	$ 58,295,000	$ 52,433,000
Proceeds from issuance of common stock from public offering, net of issuance costs					52,200,000
Issuance costs of Issuance of common shares				4,000,000	4,000,000
Aggregate maximum value of designated securities to be sold				$ 100,000,000	$ 100,000,000
Value of stock to be purchased by existing stockholders							$ 10,000,000
Cantor Fitzgerald & Co. [Member]
Stockholders Equity Common Stock [Line Items]
Sale of common stock in an at-the-market offering			25,000,000
Percentage of commission paid			3.00%

Controlled Equity Offering an55

Controlled Equity Offering and Public Offering of Common Stock - Schedule of Total Sales under Sales Agreement (Detail) - Cantor Fitzgerald & Co. [Member] $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares
Sale And Issue Of Shares Under Agreement [Line Items]
Total shares of common stock sold | shares	2,014,300
Average price per share | $ / shares	$ 3.25
Gross proceeds	$ 6,546
Commissions earned by Cantor	197
Other issuance costs	$ 259

Closing of Merger and Financing

Closing of Merger and Financing Transaction - Additional Information (Detail)	Sep. 17, 2013USD ($)shares	Sep. 03, 2013USD ($)$ / sharesshares	Sep. 30, 2015USD ($)$ / shares	Dec. 31, 2014USD ($)$ / shares	Mar. 31, 2014$ / shares	Dec. 06, 2013$ / shares	Jul. 31, 2013USD ($)
Business Acquisition [Line Items]
Common stock, par value (in dollars per share)			$ 0.001	$ 0.001	$ 0.001
Preferred stock, par value (in dollars per share)						$ 0.01
Percentage of common stock required to be held due to lock up			93.00%
Merger agreement, description			The Lock-up and Voting Agreements provide that such persons may sell, transfer or convey (i) up to 50% of their respective Covered Securities during the period commencing on the one-year anniversary of the Closing Date and ending on the eighteen-month anniversary of the Closing Date; and (ii) up to an aggregate of 75% of their respective Covered Securities during the period commencing on the eighteen-month anniversary of the Closing Date and ending on the two-year anniversary of the Closing Date.
Goodwill | $			$ 116,054,000	$ 93,842,000
Intellectual property, net | $			$ 63,866,000	$ 2,241,000
Series B Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Preferred stock, par value (in dollars per share)		$ 0.01
Shares to be purchased | shares		7,544,704.4
Number of common stock shares issuable for preferred stock | shares		2
Share price		$ 4
Shares issued and sold, other | shares	25,000
Gross proceeds from Securities Purchase Agreement | $	$ 100,000
Ending on Eighteen Month Anniversary [Member]
Business Acquisition [Line Items]
Percentage of covered securities			50.00%
Ending on Two Year Anniversary [Member]
Business Acquisition [Line Items]
Percentage of covered securities			75.00%
Safe Stitch Medical Inc [Member]
Business Acquisition [Line Items]
Exchange ratio		1.1533
Common stock, par value (in dollars per share)		$ 0.001
Business acquisition, share price		$ 1.08
Shares issued as Merger consideration | shares		21,109,949
Cash consideration | $		$ 293,000
Goodwill | $		93,842,000
Intellectual property, net | $		$ 10,000
Amortization period		5 years
Safe Stitch Medical Inc [Member] | Bridge Notes [Member]
Business Acquisition [Line Items]
Issuance of promissory note as part of merger transaction | $							$ 2,000,000
Stated interest per annum							8.00%
Private Placement [Member] | Series B Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Preferred stock, par value (in dollars per share)		$ 0.001

Closing of Merger and Financi57

Closing of Merger and Financing Transaction - Schedule of Purchase Price (Detail) - USD ($)	Sep. 03, 2013	Sep. 30, 2015	Dec. 31, 2014	Mar. 31, 2014	Mar. 30, 2014
Business Acquisition [Line Items]
Common shares outstanding at the date of Merger		100,102,816	63,182,806	48,855,255	244,276,923
Safe Stitch Medical Inc [Member]
Business Acquisition [Line Items]
Common shares outstanding at the date of Merger	12,350,000
Closing price per share	$ 7.60
Equity consideration	$ 93,858,000
Cash consideration	293,000
Total purchase price	$ 94,151,000

Closing of Merger and Financi58

Closing of Merger and Financing Transaction - Schedule of Allocation of Purchase Price to Net Assets Acquired (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 03, 2013
Business Acquisition [Line Items]
Goodwill	$ 116,054	$ 93,842
Safe Stitch Medical Inc [Member]
Business Acquisition [Line Items]
Cash and cash equivalents			$ 597
Accounts receivable			54
Inventory			50
Other current assets			53
Property and equipment			185
Other long-term asset			2
Intangible assets			10
Goodwill			93,842
Total assets acquired			94,793
Accounts payable and other liabilities			642
Total purchase price			$ 94,151

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Sep. 21, 2015USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2015EUR (€)
Operating Leased Assets [Line Items]
Fair value of contingent consideration		$ 24,300,000
ALF-X Surgical Robotic System Acquisition [Member]
Operating Leased Assets [Line Items]
Fair value of contingent consideration	$ 24,300,000	24,300,000
ALF-X Surgical Robotic System Acquisition [Member] | Maximum [Member]
Operating Leased Assets [Line Items]
Aggregate milestone payments | €			€ 27,500,000
ALF-X Surgical Robotic System Acquisition [Member] | License and Supply Agreements [Member]
Operating Leased Assets [Line Items]
Commitments under agreements, remainder of 2015		250,000
Commitments under agreements, in 2016		850,000
Commitments under agreements, in 2017		950,000
Commitments under agreements, in 2018		675,000
Commitments under agreements, thereafter until termination in 2027		$ 3,400,000

Segment and Enterprise Wide D60

Segment and Enterprise Wide Disclosures - Additional Information (Detail)	3 Months Ended	9 Months Ended
	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)Segment	Sep. 30, 2014USD ($)	Sep. 21, 2015USD ($)	Dec. 31, 2014USD ($)
Segment Reporting Information [Line Items]
Number of business segments | Segment		1
Goodwill		$ 116,054,000			$ 93,842,000
Sales	$ 61,000		$ 267,000
ALF-X Surgical Robotic System Acquisition [Member]
Segment Reporting Information [Line Items]
Goodwill				$ 22,315,000
U.S. [Member]
Segment Reporting Information [Line Items]
Percentage of total consolidated assets		57.00%
Europe [Member] | ALF-X Surgical Robotic System Acquisition [Member]
Segment Reporting Information [Line Items]
Goodwill		$ 115,600,000
International [Member]
Segment Reporting Information [Line Items]
Percentage of total consolidated assets, excluding goodwill		35.00%
Sales		$ 0	$ 0